Investor Presentaiton
Investor presentation
ADA 2019
The PIONEER 6 trial investigated cardiovascular safety of
oral semaglutide vs placebo
Slide 15
PIONEER 6 trial design
Oral semaglutide 14 mg + standard
of care
Randomised:
3,176 patients
with type 2
diabetes
Placebo + standard of care
Trial objective
137 MACE
Confirm the cardiovascular safety of oral semaglutide in
patients with type 2 diabetes
Inclusion criteria
• Age ≥50 years and clinical evidence of CV disease or age
≥50 years and subclinical evidence of CV disease
• Antidiabetic drug-naïve or current treatment with one or
more oral or injectable antidiabetic agent(s) (excl. DPP-4
and GLP-1)
PIONEER 6 headline results
21% non-significant reduction of
primary endpoint¹ for oral semaglutide-treated
patients compared to
placebo-treated subjects (HR: 0.79)
-
CV death significant (HR: 0.49)
Non-fatal MI - non-significant (HR: 1.18)
Non-fatal stroke - non-significant (HR: 0.74)
All-cause mortality - significant (HR: 0.51)
Results were based on 137 MACE with median
follow-up of 16 months
PIONEER symposium on Tuesday June 11th
from 9.45 - 11.45 (pacific time)
1 The primary endpoint of the PIONEER 6 trial was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
CV: cardiovascular; DPP-4: dipeptidyl peptidase-4 inhibitor; GLP-1: glucagon-like peptide-1; MACE: major cardiovascular event; HR: hazard ratio; MI: myocardial infarction; PIONEER: peptide
innovation for early diabetes treatment
novo nordiskView entire presentation